Physician profile
Jerome Schwartz
NPI 1396782769
$1,663.48
in general payments reported to CMS, 2019-2025
12 companies · $399 in 2025
The $399 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $36.86 · 2021: $130 · 2022: $126 · 2023: $323 · 2024: $322 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,044.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $429.52 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $318.90 | 2023-2025 | Dupixent |
| Genzyme Corporation | $238.85 | 2023-2025 | |
| Acclarent, INC | $182.24 | 2019-2021 | |
| Medtronic USA, INC. | $160.70 | 2019 | |
| Optinose US, INC. | $143.57 | 2019-2025 | |
| Aerin Medical INC. | $70.75 | 2024-2025 | |
| Smith+Nephew, INC. | $46.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.28 | 2022 | |
| Amgen INC. | $20.08 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.18 | 2025 | Voquezna |
| Hikma Pharmaceuticals USA | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.